Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections
- PMID: 3046481
- PMCID: PMC172286
- DOI: 10.1128/AAC.32.6.802
Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections
Abstract
To investigate whether 10 days of rifampin-trimethoprim (RIF-TMP) or 6 weeks of sulfamethoxazole-trimethoprim (SMX-TMP) would decrease the relapse rate in patients with acute uncomplicated upper urinary tract infections in comparison with 10 days of SMX-TMP, we randomized 189 patients to receive RIF-TMP or SMX-TMP in a ratio of 1:2. After the site of infection was established by the antibody-coated bacterium (ACB) test, patients with upper-tract infections who received SMX-TMP were again randomized and received either a total of 6 weeks or 10 days of therapy. All patients who received RIF-TMP were treated for 10 days. Clinical and microbiological evaluations were repeated at 2 and 6 weeks posttreatment. Eighty-five patients (54 ACB positive) received 10 days of RIF-TMP, 71 patients (45 ACB positive) received 10 days of SMX-TMP, and 18 patients (18 ACB positive) received 6 weeks of SMX-TMP. The overall recurrence rates in patients who received 10 days of therapy were 32% for RIF-TMP and 23% for SMX-TMP (P = 0.13). There were 12 (14%) relapses in the RIF-TMP group compared with 2 (3%) relapses in the SMX-TMP group (P = 0.01). In patients with upper-tract infections, the relapse rates were not statistically significantly different (P = 0.13). There were two (11%) recurrences (one relapse and one reinfection) in the 6-week treatment group. This 6% relapse rate was not different from the 4% relapse rate observed in patients with upper-tract infections who received 10 days of SMX-TMP. The number of patients who discontinued treatment because of an adverse effect in the 6-week SMX-TMP treatment group was significantly greater than those in the 10-day SMX-TMP treatment group (P=0.003) and the RIF-TMP treatment group (P=0.05). Ten days of SMX-TMP was as effective as 6 weeks of SMP-TMP or 10 days of RIF-TMP in the treatment of uncomplicated upper urinary tract infections and caused the fewest untoward effects.
Similar articles
-
Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI.Int J Antimicrob Agents. 2002 Jun;19(6):554-6. doi: 10.1016/s0924-8579(02)00104-8. Int J Antimicrob Agents. 2002. PMID: 12135847 Review.
-
Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.Ann Intern Med. 2001 Jul 3;135(1):41-50. doi: 10.7326/0003-4819-135-1-200107030-00012. Ann Intern Med. 2001. PMID: 11434731 Review.
-
Combination of trimethoprim and methenamine hippurate in the treatment of acute urinary tract infections.Scand J Infect Dis. 1983;15(2):201-6. doi: 10.3109/inf.1983.15.issue-2.13. Scand J Infect Dis. 1983. PMID: 6603654 Clinical Trial.
-
Rifaprim in urinary tract infection: a comparison with co-trimoxazole.J Antimicrob Chemother. 1983 Mar;11(3):239-44. doi: 10.1093/jac/11.3.239. J Antimicrob Chemother. 1983. PMID: 6601648 Clinical Trial.
-
A comparison of trimethorprim-sulfamethoxazole with sulfamethoxazole alone in infections localized to the kidneys.Can Med Assoc J. 1975 Jun 14;112(13 Spec No):9-12. Can Med Assoc J. 1975. PMID: 1093658 Free PMC article. Clinical Trial.
Cited by
-
Systemic antibiotic therapy for chronic osteomyelitis in adults.Clin Infect Dis. 2012 Feb 1;54(3):393-407. doi: 10.1093/cid/cir842. Epub 2011 Dec 12. Clin Infect Dis. 2012. PMID: 22157324 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical